Komori
General Meetings of Shareholders4556KAINOS Laboratories,Inc.Pharmaceuticals

Notice Regarding the Setting of a Record Date for Convening an Extraordinary General Meeting of Shareholders

A record date of 10 April 2026 was set to determine the shareholders entitled to exercise voting rights in preparation for the possibility of holding an extraordinary general meeting of shareholders. The date and time of the meeting and the details of the proposals have not yet been determined.

Worth reading
34Immaterial
Scored from 3 of 4 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Extraordinary (meeting number: Not disclosed)
Date and timeScheduled for late May 2026 (start time: Not disclosed)
Matters for resolution1 item
  1. The proposals are expected to include a share consolidation and an amendment to the Articles of Incorporation to abolish the provision prescribing the number of shares constituting one unit, conditional on the share consolidation taking effect. However, the details of the formal proposals are Not disclosed.

Shareholder Proposal

None. Although the offeror is expected to request the holding of an extraordinary general meeting of shareholders, including proposals, this is not described as a shareholder proposal.

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingExtraordinary (meeting number: Not disclosed)
Date and timeScheduled for late May 2026 (start time: Not disclosed)
Matters for resolutionThe proposals are expected to include a share consolidation and an amendment to the Articles of Incorporation to abolish the provision prescribing the number of shares constituting one unit, conditional on the share consolidation taking effect. However, the details of the formal proposals are Not disclosed.
Shareholder ProposalNone. Although the offeror is expected to request the holding of an extraordinary general meeting of shareholders, including proposals, this is not described as a shareholder proposal.
Items this document does not state (2)
Director nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

If the offeror is unable to acquire all shares following the tender offer, it is expected to request that an extraordinary general meeting of shareholders be held, with proposals for a share consolidation and an amendment to the Articles of Incorporation to abolish the provision prescribing the number of shares constituting one unit.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Setting of a Record Date for Convening an Extraordinary General Meeting of Shareholders | KAINOS Laboratories,Inc. (4556) timely disclosure | Komori